EMA Authorised: Exblifep (cefepime dihydrochloride monohydrate;Enmetazobactam) — Advanz Pharma Limited

View source ↗

Summary

Exblifep has been authorised for multiple infections including urinary tract infections, pyelonephritis, healthcare-associated pneumonia, and ventilator-associa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Healthcare-associated Pneumonia
• Pyelonephritis
• Urinary Tract Infection
• Ventilator-associated Pneumonia

Drugs mentioned

• Exblifep
• cefepime dihydrochloride monohydrate; Enmetazobactam

Snippet

Status: Authorised. Therapeutic area: Urinary Tract Infections;Pyelonephritis;Healthcare-Associated Pneumonia;Pneumonia, Ventilator-Associated. MAH: Advanz Pharma Limited. Decision date: 21/03/2024